Basic Information
Hemangiol
Regulatory Information
EMEA/H/C/002621
April 23, 2014
February 20, 2014
6
February 9, 2023
Company Information
France
Les Cauquillous 81500 - Lavaur
PIERRE FABRE MEDICAMENT
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: - Life- or function-threatening haemangioma, - Ulcerated haemangioma with pain and/or lack of response to simple wound care measures, - Haemangioma with a risk of permanent scars or disfigurement. It is to be initiated in infants aged 5 weeks to 5 months.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Hemangiol. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Hemangiol. For practical information about using Hemangiol, patients should read the package leaflet or contact their doctor or pharmacist.